Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation with postponed donor lymphocyte infusion in elderly acute myeloid leukemia and high risk myelodysplasia patients

Trial Profile

Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation with postponed donor lymphocyte infusion in elderly acute myeloid leukemia and high risk myelodysplasia patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amsacrine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Alemtuzumab; Antithymocyte globulin; T cell replacement therapy
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLAMSA-TCD-NMA-AlloSCT
  • Most Recent Events

    • 01 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top